AS vs. SpA Responses with Combination Treatment Save

Patients in a large Swedish registry with ankylosing spondylitis (AS) and spondyloarthritis (SpA) who started a TNF inhibitor were followed for comedication use and TNF inhibitor survival.  1365 patients with AS and 1155 patients with uSpA were folllow and between 40.8% and 50.3% used DMARD comedication during the study period. The 5 year TNF inhibitor survival was better in AS, but not SpA, when a background DMARD was continued.